Clinical trials for Angioedema

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Angioedema. For all clinical trials, go to clinical trials search

This list shows clinical trials for Angioedema

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Angioedema
Title Recruitment status Location
HELP Study (TM): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE) Recruiting United Kingdom
A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema Recruiting United Kingdom
Firazyr® Patient Registry Protocol (Icatibant Outcome Survey - IOS) Recruiting United Kingdom
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU Recruiting United Kingdom
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema Recruiting United Kingdom
AWARE - Chronic Urticaria Recruiting United Kingdom
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema Not recruiting United Kingdom
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema Not recruiting United Kingdom
Open-Label, Multicenter Study to Evaluate Safety, Local Tolerability, Convenience, and Efficacy of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary Angioedema - EASSI - Evaluation of the Safety of Self-administration with Icatibant Not Recruiting United Kingdom
OPuS2 - A study to assess two doses of BCX4161 in the prevention of HAE attacks in patients over a 12 week period Not Recruiting United Kingdom

Page last reviewed:

Next review due: